Please login to the form below

Not currently logged in
Email:
Password:

Teva halts development of Nuvigil in bipolar disorder

Shelves plan to expand use of sleep disorder therapy

Teva Nuvigil armodafinil

Teva Pharmaceutical has halted a programme investigating the use of its sleep disorder treatment Nuvigil to treat depression after disappointing late-stage trial results.

The Israel-based pharma company said that Nuvigil (armodafinil) failed to demonstrate it was significantly more effective than placebo during a phase III trial investigating its use as an adjunct therapy in adults with major depression associated with bipolar I disorder.

As a result, Teva said it “will not proceed with regulatory filings” for the drug in this indication despite good results in secondary endpoints, such as responder rate and remission.

“While this study demonstrated a numerical improvement, we are disappointed that armodafinil did not reach statistical significance,” said Dr Michael Hayden, Teva's president of global R&D and chief scientific officer.

Teva gained the rights to Nuvigil as part of its acquisition of Cephalon in 2011, and markets the drug to improve wakefulness in adults who experience excessive sleepiness due to sleep disorders, such as sleep apnea or narcolepsy.

Nuvigil made $347m for Teva during 2012 in these indications, but the company was keen to expand its use ahead of patent expiry in 2016.

Early trial results studying the drug as a depression treatment were promising, including a successful phase III study reported in May 2012, with Teva's head of global medicines John Congleton commenting at the time that the company could launch the drug for bipolar disorder as early as 2014.

However, cracks began to show at the beginning of the year when the company posted disappointing results from another phase III trial, and these concerns have now been confirmed following the latest data.

Any further plans to expand the use of the product now seem unlikely, with Dr Hayden commenting: “We will continue to focus on our current Nuvigil indications.”

Article by
Thomas Meek

3rd September 2013

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Solaris Health

The beauty of detail: an effective, compelling medical communications campaign requires each component to be carefully planned, expertly crafted and...

Latest intelligence

The truth is out there: Patients first
Patient centricity, patient focus, patients first – words that are on everyone’s lips these days. But what do they really mean? Where does the patient voice fit in? And what...
mHealth: The revolution will not be digital
Could mHealth, which has been growing exponentially in recent years, be the answer we have been looking for to address our population health challenge? Could mHealth save healthcare?...
Medical information in precision medicine
Global Medical Information Leader James Oughton reveals the top trends in medical information and precision medicine....

Infographics